Our findings elucidate a unique and synergistic advantage of STING agonism as a therapeutic strategy in treating metastatic bone cancer pain and its comorbidities, including tumor-induced bone destruction and functional impairment (e.g., immobility). The gene discussed is STING1; the disease is neoplasm.